Ofatumumab resistance management

OfatumumabOfatumumab is a drug used to treat certain types of leukemia and multiple sclerosis. There is data showing that continued ofatumumab treatmenthas sustained efficacy in patients with relapsed multiple sclerosis (RMS) for more than 5 years. Patients treated with ofatumumab had significantly lower relapse rates, fewer MRI lesions, and a higher rate of no evidence of disease activity (NEDA-3).

Ofatumumab is a prescription drug and patients should use this drug under the guidance of a doctor. If patients show signs of disease recurrence or progression, testing should be performed to confirm the presence of ofatumumab resistance. This may involve blood tests, bone marrow tests, etc. In the case of ofatumumab resistance, consider combination with other drugs. Combining drugs can enhance the effectiveness of treatment and may reduce the risk of drug resistance. If resistance is confirmed and the risk of resistance is high, your doctor may recommend switching to a different treatment or regimen. In some disease conditions, there may be ongoing clinical trials designed to investigate new treatments or drugs. Physicians may consider enrolling patients in relevant clinical trials for opportunities for further treatment.

The original drug of ofatumumab has been launched in China and has also been included in medical insurance. Only patients who meet the indications can be reimbursed. The price is around tens of thousands of yuan, and domestic purchase channels are relatively difficult. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.